title: High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis.
abstract: Tuberculosis remains a major health problem due to the emergence of drug-resistant strains of Mycobacterium tuberculosis. Some models have provided valuable information about drug resistance and efficacy; however, the translation of these results into effective human treatments has mostly proven unsuccessful. In this study, we adapted high-content screening (HCS) technology to investigate the activities of antitubercular compounds in the context of an in vitro granuloma model. We observed significant shifts in the MIC50s between the activities of the compounds under extracellular and granuloma conditions.
authors.affiliation: INSERM-U892, CNRS UMR 6299, Université de Nantes, Nantes, France.
authors.forename: Mayra
authors.initials: M
authors.lastname: Silva-Miranda
authors.affiliation: INSERM-U892, CNRS UMR 6299, Université de Nantes, Nantes, France.
authors.forename: Euloge
authors.identifier: http://orcid.org/0000-0002-8552-8925
authors.initials: E
authors.lastname: Ekaza
authors.affiliation: INSERM-U892, CNRS UMR 6299, Université de Nantes, Nantes, France.
authors.forename: Adrien
authors.initials: A
authors.lastname: Breiman
authors.affiliation: Laboratoire UPRES EA3826, Thérapeutiques Cliniques et Expérimentales des Infections, Faculté de Médecine, Université de Nantes, Nantes, France CHU Nantes, Pôle Anesthésie Réanimations, Service d'Anesthésie Réanimation Chirurgicale, Hôtel Dieu, Nantes, France.
authors.forename: Karim
authors.initials: K
authors.lastname: Asehnoune
authors.affiliation: Diseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain.
authors.forename: David
authors.initials: D
authors.lastname: Barros-Aguirre
authors.affiliation: Inserm Avenir, Institut Pasteur Korea, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea.
authors.forename: Kevin
authors.initials: K
authors.lastname: Pethe
authors.affiliation: Inserm Avenir, Institut Pasteur Korea, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea.
authors.forename: Fanny
authors.initials: F
authors.lastname: Ewann
authors.affiliation: Inserm Avenir, Institut Pasteur Korea, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea INSERM-U1019, CNRS UMR8204, Université de Lille, Nord de France, Institut Pasteur de Lille, Center for Infection and Immunity, Lille, France.
authors.forename: Priscille
authors.initials: P
authors.lastname: Brodin
authors.affiliation: Diseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain.
authors.forename: Lluís
authors.initials: L
authors.lastname: Ballell-Pages
authors.affiliation: INSERM-U892, CNRS UMR 6299, Université de Nantes, Nantes, France frederic.altare@inserm.fr.
authors.forename: Frédéric
authors.initials: F
authors.lastname: Altare
mesh_terms: D000995:Antitubercular Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006099:Granuloma / Q000188:drug therapy*; D057166:High-Throughput Screening Assays / Q000379:methods*; D006801:Humans; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy
chemical_list: D000995:Antitubercular Agents